OncoLink Cancer Treatment and Resources

Oncolink Features

Find My Cancer Drug

OncoLink Cancer Treatment and Resources

Tipos de Cancer / Leucemia / Leucemia de Célula Pilosa / Recursos de NCI

Link to OncoLink

NCI CANCERLIT^® Search: Hairy Cell Leukemia - March 2002

Imprima English

National Cancer Institute^®
Ultima Vez Modificado: 1 de marzo del 2002

Relapse in hairy cell leukemia due to isolated nodular skin infiltration.

Hairy cell leukaemia--therapeutic options.

2-CdA in the treatment of hairy cell leukaemia.

Successful treatment with low-dose splenic irradiation for massive splenomegaly in an elderly patient with hairy-cell leukemia.

Interferon-alpha 2b and vesnarinone influence levels of tumor necrosis factor-alpha, apoptosis, or interleukin 6 in ESKOL, a hairy cell

Risk of second cancer in patients with hairy cell leukemia: long-term follow-up.

Table of Contents

1
UI - 11554237
AU - Yetgin S; Olcay L; Yenicesu I; Oner AF; Caglar M
TI - Relapse in hairy cell leukemia due to isolated nodular skin infiltration.
SO - Pediatr Hematol Oncol 2001 Sep;18(6):415-7
Leukemic skin infiltration is quite uncommon in certain types of leukemia. Here, a child with hairy cell leukemia who developed isolated skin infiltration during remission is reported. The failure to diagnose the leukemic infiltration until the nodule reached a diameter of 2 cm is emphasized.

2
UI - 11837463
AU - Srivastava A; Mathews V
TI - Hairy cell leukaemia--therapeutic options.
SO - J Assoc Physicians India 2001 Aug;49():783-4

3
UI - 11837464
AU - Abhyankar D; Bajpai S; Saikia T; Gopal R; Nair CN; Advani SH
TI - 2-CdA in the treatment of hairy cell leukaemia.
SO - J Assoc Physicians India 2001 Aug;49():785-7
AD - Department of Medical Oncology, Tata Memorial Hospital, Mumbai.
INTRODUCTION: Hairy cell leukaemia (HCL) is a rare lymphoproliferative disorder. Treatment options available are splenectomy, interferon, DCF and 2-CdA. 2-CdA is considered to have curative potential as proved by the other studies. METHODS: We gave 2-CdA in a dose of 0.09/kg/day as a continuous infusion in sixteen patients of hairy cell leukaemia. RESULTS: Three patients developed neutropenia post transfusion. At the end of three months all patients were in remission. Two patients relapsed at the median follow-up of 15 months. CONCLUSION: 2-CdA in HCL can achieve complete remission, prolonged survival and care as well.

4
UI - 11860448
AU - Nishii K; Katayama N; Maeda H; Usui E; Takemitu T; Lorenzo V F; Nakase
TI - K; Shiku H Successful treatment with low-dose splenic irradiation for massive splenomegaly in an elderly patient with hairy-cell leukemia.
SO - Eur J Haematol 2001 Oct;67(4):255-7
AD - Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Mie, Japan. kaz@clin.medic.mie-u.ac.jp
The therapeutic approach to hairy-cell leukemia (HCL) is in some instances still debated. Although management with alpha-interferon and purine analogues is well established, there is an alternative role for therapeutic splenectomy in patients with massive splenomegaly who have failed to respond to systemic therapy. Most patients with HCL will not be suitable for treatment with splenectomy as their ages at diagnosis are high. Here, we report an elderly Japanese HCL patient whose refractory massive splenomegaly responded well to low-dose splenic irradiation.

5
UI - 11755467
AU - Khalaf W; Maina C; Byers J; Harvey W
TI - Interferon-alpha 2b and vesnarinone influence levels of tumor necrosis factor-alpha, apoptosis, or interleukin 6 in ESKOL, a hairy cell leukemic cell line. A potential cytokine and oncogene relationship regulating apoptosis is suggested.
SO - Leuk Res 2002 Feb;26(2):169-77
AD - Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46222, USA.
The in vitro effects of interferon-alpha (IFN) on levels of secreted interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF alpha), and nuclear matrix proteins (NMP) were examined in ESKOL, a B-lymphoblastoid cell line resembling hairy cell leukemia (HCL). IFN enhances differentiation in ESKOL, decreases TNF alpha levels, decreases apoptosis, increases IL-6 levels, and down regulates the expression of several oncogenes. Vesnarinone (Ves), a TNF alpha repressor, lowers TNF-alpha and decreases apoptosis in the same cell line. ESKOL exhibits enhanced apoptosis and reduced B-cell lymphomas (Bcl-2) levels over WIL-2. IL-6 and TNFalpha have been shown to decrease and increase apoptosis in B-cells respectively; however, treatment of ESKOL with these cytokines had no significant effect on apoptosis. We suggest that IFN decreases apoptosis by mechanisms involving enhanced IL-6 and Bcl-2 levels, decreased TNF alpha and the down regulation of apoptotic oncogenes, including c-myc.

6
UI - 11821443
AU - Federico M; Zinzani PL; Frassoldati A; Vinceti M; Mode A; Annino L;
TI - Chisesi T; Pagnucco G; Invernizzi R; Spriano M; Resegotti L; Bendandi M; Damasio EE; Italian Cooperative Group for the Study of Hairy Cell Leukemia Risk of second cancer in patients with hairy cell leukemia: long-term follow-up.
SO - J Clin Oncol 2002 Feb 1;20(3):638-46
AD - Oncologia Medica and Dipartimento di Scienze Igienistiche, Universita di Modena e Reggio Emilia, Modena, Italy. federico@unimo.it
PURPOSE: The purpose of the present study was to assess the risk of second cancers in patients with hairy cell leukemia (HCL). PATIENTS AND METHODS: We investigated the incidence of additional cancers in those patients registered in the nationwide registry of the Italian Cooperative Group for the Study of HCL, asking the cooperating centers for additional information on initial and subsequent therapies and on time and type of second malignancies, if they developed. Here we report the final results of this survey, consisting of 54 cases of second malignancies (excluding nine cases of epithelial skin cancer) which developed in 54 patients of 1,022 with adequate follow-up. RESULTS: The cumulative risk of development of a second cancer was 5%, 10%, and 14% at 5, 10, and 15 years, respectively. The incidence of second malignancies was not significantly higher than the expected rate (standardized incidence ratio [SIR], 1.01; 95% confidence interval [CI], 0.74 to 1.33; P = 1.0). However, the SIR of non-Hodgkin's lymphoma in the entire cohort was 5.3 (95% CI, 1.9 to 11.5). Second malignancies occurred in eight (4.7%) of 386 patients who never received interferon (IFN), nine (5.9%) of 495 patients treated with IFN at the time of diagnosis, and seven (6.9%) of 102 patients who received IFN as second-line therapy. These differences were not statistically significant. Analysis of the separate calendar periods did not reveal any particular trends with respect to variations in SIR. CONCLUSION: The present study does not support the suspicion that patients with HCL are at increased risk of additional second malignancies, although the incidence of lymphoid neoplasms was significantly higher than expected. In addition, our data indicate that IFN therapy did not exert an oncogenic effect in such patients.

The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.

OncoLink Cancer Treatment and Resources

OncoLink I wish u knew...

Marianna talks about what makes a great oncology nurse and how the experience of caring for people with cancer is a rewarding career. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews

Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement